Starget Pharma operates in the United States and Israel and focuses on developing peptide-based radioligand therapies (RLTs) for oncology indications. Its proprietary in-silico, AI-driven discovery platform rapidly identifies and prioritizes radioligand candidates, positioning the company as, in management’s words, the only RLT firm with an AI-powered peptide discovery engine. The lead program is a first-in-class SSTR3-targeted theranostic pair intended for sarcoma, neuroendocrine tumors, and malignant melanoma. A strategic collaboration with the Center for Molecular Imaging and Therapy (CMIT) supplies downstream capabilities in imaging, radiochemistry, clinical research, and manufacturing, creating an end-to-end pathway from discovery through early-phase trials. Multiple clinical entries are planned for 2026, supported by newly secured capital to expand U.S. translational and manufacturing infrastructure. Though still pre-revenue, the company’s clinical-stage designation and AI platform aim to generate a repeatable pipeline of RLT programs.

Total raised

$18M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2026